https://chinahealthreport.com/article/907517369-leukemia-inhibitory-factor-market-to-surpass-2-65-billion-by-2033-at-9-2-cagr-coherent-market-insights China Health Report en PressRelease 2026-04-23T12:08:10+00:00 Leukemia Inhibitory Factor Market to Surpass $2.65 Billion by 2033 at 9.2% CAGR: Coherent Market Insights https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24839339-leukemia-inhibitory-factor-mark-1024x1024.jpeg https://chinahealthreport.com/article/907588857-itonic-holdings-ltd-granted-an-extension-of-additional-180-day-by-nasdaq-to-regain-compliance-with-minimum-bid-price-rule China Health Report en PressRelease 2026-04-23T20:05:00+00:00 iTonic Holdings Ltd Granted An Extension of Additional 180-Day by Nasdaq to Regain Compliance with Minimum Bid Price Rule https://ml.globenewswire.com/media/7785d449-a9e0-4ea1-86eb-ff46d45db4db/small/phetonlogo-jpg.jpg https://chinahealthreport.com/article/907548326-innocare-releases-2026-q1-results-strong-revenue-growth-and-sustained-profitability China Health Report en PressRelease 2026-04-23T13:20:49+00:00 InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability https://ml.globenewswire.com/media/2dc70b00-a0b0-4d85-adef-2717a7067aec/small/innocare-eng-logo-horizontal-png.png